TITLE

Battle for bevacizumab for wet AMD: sight- and cost-saving?

PUB. DATE
November 2017
SOURCE
PharmacoEconomics & Outcomes News;11/18/2017, Vol. 791 Issue 1, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
126306607

 

Related Articles

  • Bevacizumab versus Ranibizumab on As-Needed Treatment Regimen for Neovascular Age-Related Macular Degeneration in Turkish Patients. Ozkaya, Abdullah; Alkin, Zeynep; Karakucuk, Yalcin; Yasa, Dilek; Taylan Yazici, Ahmet; Demirok, Ahmet // ISRN Ophthalmology;2013, p1 

    Purpose. To compare the efficacy of intravitreal bevacizumab versus ranibizumab in the treatment of neovascular age-related macular degeneration (nAMD).Methods. Retrospective, comparative study. The newly diagnosed nAMDpatients who were treated with intravitreal bevacizumab or ranibizumab on an...

  • Review: Avastin & Lucentis Equally Safe in AMD Patients.  // Review of Ophthalmology;Oct2014, Vol. 21 Issue 10, p4 

    The article offers information on a study published in the September 2014 issue of the periodical "Cochrane Review" on comparison between two drugs ranibizumab and bevacizumab used for the treatment of age-related macular degeneration (MD). Topics discussed include application of bevacizumab and...

  • One year results of a phase 1 study of the safety and tolerability of combination therapy using sustained release intravitreal triamcinolone acetonide and ranibizumab for subfoveal neovascular AMD. Lim, Jennifer I.; Niec, Marcia; Wong, Vernon // British Journal of Ophthalmology;May2015, Vol. 99 Issue 5, p618 

    Purpose To investigate safety and evidence of efficacy of IBI-20089, an intravitreal, liquid, sustained drug delivery system formulated with triamcinolone acetonide (TA) in combination with ranibizumab (Lucentis) for neovascular age related macular degeneration. Methods Patients received a...

  • The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters. Elshout, Mari; Reis, Margriet; Webers, Carroll; Schouten, Jan // Graefe's Archive of Clinical & Experimental Ophthalmology;Dec2014, Vol. 252 Issue 12, p1911 

    Background: Age-related macular degeneration (AMD) is a blinding disease placing considerable burden on society due to blindness-associated costs. Intravitreal anti-vascular endothelial growth factors (anti-VEGFs) are effective in reducing the incidence of blindness, but at potentially high...

  • Paired responses to intravitreal bevacizumab in diabetic macular edema: predictors of response in the fellow eye. Karth, Peter; Chang, Anne; Wirostko, William // Graefe's Archive of Clinical & Experimental Ophthalmology;Feb2014, Vol. 252 Issue 2, p207 

    Background: Factors predictive for response of diabetic macular edema (DME) to intravitreal bevacizumab (IVB) remain unclear. In this study, we assess the predictability of DME response to IVB based on the response to IVB in a previously treated fellow eye and other known pre-injection factors...

  • Ranibizumab for Eyes Previously Treated With Pegaptanib or Bevacizumab Without Clinical Response. Kaiser, Richard S.; Gupta, Omesh P.; Regillo, Carl D.; Ho, Allen C.; Fineman, Mitchell S.; Vander, James F.; McNamara, J. Arch; Brown, Gary C. // Ophthalmic Surgery, Lasers & Imaging;Jan/Feb2012, Vol. 43 Issue 1, p13 

    BACKGROUND AND OBJECTIVE: To assess the safety and efficacy of ranibizumab in patients who had inadequate response to pegaptanib or bevacizumab. PATIENTS AND METHODS: In this single-center study, 19 patients with subfoveal choroidal neovascularization secondary to age-related macular...

  • Doctors warn against using Avastin for patients with macular degeneration. Kmietowicz, Zosia // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;5/15/2010, Vol. 340 Issue 7755, p1052 

    The article focuses on a warning issued by British ophthalmologists on the possible risks associated with the use of bevacizumab (Avastin) for treating wet age related macular degeneration.

  • Study: Cardiovascular risk not affected by AMD therapies. Curtis, Lesley H. // Ocular Surgery News Europe;May2011, Vol. 22 Issue 5, p22 

    The article discusses a retrospective study which showed that age-related macular degeneration (AMD) treatment with ranibizumab or bevacizumab may not be associated with increased cardiovascular risks.

  • Avastin safety in AMD.  // Optometry Today;10/3/2014, Vol. 54 Issue 19, p52 

    The article reports on research as of October 2014 which shows that no data is available supporting the claim that ranibizumab is safer to use than the cheaper bevacizumab for age-related macular degeneration (AMD).

  • Ranibizumab.  // Reactions Weekly;Oct2015, Vol. 1572 Issue 1, p177 

    The article presents case studies of a 74-year-old man and a 90-year-old woman who developed resistance to ranibizumab during treatment for exudative age-related macular degeneration (AMD).

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics